AlphaBio SA develops commercially a novel anti-mycotic, for topical usage for skin infections due to fungi (dermatophytosis). This drug is already used as an anti-bacteria and is known to be safe. From its mode of action, it is likely that AlphaBio’s product will be effective even against fungi that are resistant to most current anti-fungal agents. Resistance to anti-fungal agents has indeed become a major public health issue.
